Reaching complete or near-complete resolution of psoriasis: benefit and risk considerations-Reference-Cited by-同舟云学术

Reaching complete or near-complete resolution of psoriasis: benefit and risk considerations

Published:2017-07-03 Issue:2 Volume:177 Page:587-590
ISSN:0007-0963
Container-title:British Journal of Dermatology
language:en
Short-container-title:Br J Dermatol

Author:

Blauvelt A.¹^ORCID,Griffiths C.E.M.²,Lebwohl M.³,Mrowietz U.⁴,Puig L.⁵^ORCID,Ball S.⁶,Zhang L.⁶,Edson-Heredia E.⁶,Warner M.⁶,Zhu B.⁶,Lin C-Y.⁶,Nikaï E.⁷,Dey D.⁶,Mallbris L.⁶,Reich K.⁸^ORCID

Affiliation:

1. Oregon Medical Research Center; Suite G, 9495 S. Locust Street Portland OR 97223 OR U.S.A

2. Dermatology Centre; Salford Royal Hospital, University of Manchester, Manchester Academic Health Science Centre; Manchester U.K

3. Department of Dermatology; Icahn School of Medicine at Mount Sinai; New York City NY U.S.A

4. Psoriasis Center at the Department of Dermatology; University Medical Centre Schleswig-Holstein; Campus Kiel Germany

5. Department of Dermatology; Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona; Barcelona Catalonia Spain

6. Eli Lilly and Co.; Indianapolis IN U.S.A

7. Eli Lilly Belgium; Brussels Belgium

8. Dermatologikum Hamburg; Hamburg Germany

Funder

Eli Lilly and Company

Publisher

Wiley

Subject

Dermatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjd.15463/fullpdf

Reference10 articles.

1. Clinical meaningfulness of complete skin clearance in psoriasis;Strober;J Am Acad Dermatol,2016

2. Differences in psoriasis signs and symptom severity between patients with clear and almost clear skin in clinical practice;Feldman;J Dermatolog Treat,2016

3. Total skin clearance results in improvements in health-related quality of life and reduced symptom severity among patients with moderate to severe psoriasis;Viswanathan;J Dermatolog Treat,2015

4. Essential truths for the care and management of moderate-to-severe psoriasis;Blauvelt;J Drugs Dermatol,2015

5. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials;Griffiths;Lancet,2015

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost per responder for methotrexate versus other therapies in patients with moderate-to-severe plaque psoriasis in Italy;Global & Regional Health Technology Assessment;2022-11-10

2. Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational psoriasis study of health outcomes ( PSoHO );Journal of the European Academy of Dermatology and Venereology;2022-07-29

3. Long‐term, durable, absolute Psoriasis Area and Severity Index and health‐related quality of life improvements with risankizumab treatment: a post hoc integrated analysis of patients with moderate‐to‐severe plaque psoriasis;Journal of the European Academy of Dermatology and Venereology;2022-03-17

4. Higher rates of skin clearance and efficacy in challenging body areas are associated with better health‐related quality of life following ixekizumab maintenance treatment in pediatric patients with plaque psoriasis;Pediatric Dermatology;2021-12-20

5. Association Between Patient- and Physician-Reported Outcomes in Patients with Moderate-To-Severe Plaque Psoriasis Treated with Biologics in Real Life (PSO-BIO-REAL);Dermatology and Therapy;2020-08-06